Europe postpones decision on Bristol immune system cancer drug

March 27, 2015 12:52 PM

14 0

LONDON (Reuters) - European regulators have postponed a decision on whether to recommend approval of a closely watched Bristol-Myers Squibb drug that helps the immune system fight cancer, a spokeswoman for the European Medicines Agency said on Friday.

Bristol's nivolumab, which is already approved in the United States under the brand name Opdivo for melanoma and lung cancer, was on the agenda at this month's meeting of agency experts on new drugs - but in the event no verdict was reached.

Also read: Rhode Island on track for $32M budget surplus

Read more

To category page